A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

Inclusion Criteria: * Male and female participants aged 18 to 65 with previously confirmed diagnosis of Fabry disease and a history of clinical symptoms of Fabry disease. * Participants may be receiving treatment with agalsidase alfa, agalsidase beta, or migalastat, or may be untreated. * Left ventricular hypertrophy. * Contraception for male or female participants: not pregnant or breastfeeding; no sperm donating for male participant. * A signed informed consent must be provided prior to any study-related procedures. Exclusion Criteria: * History of transient ischemic attack, stroke, myocardial infarction, heart failure, major cardiovascular surgery or kidney transplantation. * History of seizures currently requiring treatment. * Underlying medical condition that may cause or contribute to left ventricular hypertrophy. * Asymmetric hypertrophy by cardiac MRI at screening if considered by central reader to be not related to Fabry disease. * Advanced cardiac fibrosis, defined as significant late gadolinium enhancement affecting 3 or more segments involving \>50% of myocardial thickness on screening cardiac MRI. * History of clinically significant cardiac arrhythmia. Atrial fibrillation that is well controlled on a stable medical regimen for at least 12 months is not an exclusion if the CHA2DS2-VASc score is 0 for males or 1 for females. * Estimated glomerular filtration rate \<45 mL/min/1.73m2. * Presence of severe depression as measured by Beck's Depression Inventory (BDI)…